| 产品描述: | 6-methyl-2-[2-[(E)-(6-oxo-1-cyclohexa-2,4-dienylidene)methyl]hydraziny l]-1H-pyrimidin-4-one |
| 体内研究: |
SKLB325 (10 mg/kg) 在腹膜内异种移植模型中具有抗肿瘤活性。SKLB325 显著延长荷瘤小鼠的生存期,且无明显副作用。SKLB325 处理方案可有效抑制裸鼠体内的 SKOV3、ES2、CP70 和 A2780s 肿瘤生长。 |
| 参考文献: |
1. Heng Zheng, et al. Jumonji domain-containing 6 (JMJD6) identified as a potential therapeutic target in ovarian cancer. Signal Transduct Target Ther.2019 Jul 26;4:24. 2. Chuanjie Zhang, et al. Epigenome screening highlights that JMJD6 confers an epigenetic vulnerability and mediates sunitinib sensitivity in renal cell carcinoma. Clin Transl Med. 2021 Feb;11(2):e328. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
4.094 ml |
20.471 ml |
40.942 ml |
| 5 mM |
0.819 ml |
4.094 ml |
8.188 ml |
| 10 mM |
0.409 ml |
2.047 ml |
4.094 ml |
| 50 mM |
0.082 ml |
0.409 ml |
0.819 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |